Price
Target price
?
?
-0.070%
-0.02
-0.070%
€53.50
09:32 / Stuttgart Stock Exchange
WKN: A1XCY0 / Symbol: RARE / Name: Ultragenyx / Stock / Biotechnology & Medical Research / Mid Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Ultragenyx Pharmaceutical Inc. Stock
There is nearly no change for the Ultragenyx Pharmaceutical Inc. stock today. Compared to yesterday it only changed by -€0.020.
With 27 Buy predictions and not a single Sell prediction Ultragenyx Pharmaceutical Inc. is an absolute favorite of our community.
With a target price of 53 € there is a hugely positive potential of 76.2% for Ultragenyx Pharmaceutical Inc. compared to the current price of 30.08 €.
Pros and Cons of Ultragenyx Pharmaceutical Inc. in the next few years
Pros
?
S********** s********
?
W********* I********* f** t** n*** y****
?
C******** o* t** e**********
Cons
?
G***** c******* t* c**********
?
B****
?
M***** P*******
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Ultragenyx Pharmaceutical Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Ultragenyx Pharmaceutical Inc. | -0.070% | 1.038% | 54.907% | -12.575% | 73.810% | -27.723% | -60.541% |
| Ligand Pharmaceuticals | 0.000% | 1.449% | 35.922% | 184.264% | 68.675% | 324.242% | 157.117% |
| United Therapeutics | 1.010% | 0.894% | 2.645% | 95.842% | 13.527% | 151.087% | 205.094% |
| Ionis Pharmaceuticals Inc. | -12.070% | 6.237% | 15.862% | 107.349% | 8.770% | 93.965% | 125.710% |
Comments
Ultragenyx Pharmaceutical (RARE) had its price target raised by Royal Bank Of Canada from $35.00 to $40.00. They now have an "outperform" rating on the stock.
Show more
Ratings data for RARE provided by MarketBeat
Ultragenyx Pharmaceutical (RARE) had its price target raised by Cantor Fitzgerald from $84.00 to $96.00. They now have an "overweight" rating on the stock.
Show more
Ratings data for RARE provided by MarketBeat
Ultragenyx Pharmaceutical (RARE) had its price target lowered by Guggenheim from $52.00 to $43.00. They now have a "buy" rating on the stock.
Show more
Ratings data for RARE provided by MarketBeat
News
What to Know About This Fund's $5.4 Million Ultragenyx Purchase as Shares Slip 30% in One Year
On May 14, 2026, Krensavage Asset Management disclosed it bought 241,245 shares of Ultragenyx Pharmaceutical (NASDAQ:RARE), an estimated $5.43 million trade based on quarterly average pricing.
